Selecting a Compound for Drug Development – The Importance of Knowledge Management - Part 1

The panel stressed the dynamic nature of decision-making in the pharmaceutical industry, the importance of continuous monitoring, and the need for effective knowledge management to support informed choices at every stage of drug development. Challenges include decision-making in different-sized organizations, resource availability, decision-making culture, and stakeholder preferences.

Selecting a Compound for Drug Development – The Importance of Knowledge Management - Part 2

The panel discussed the decision-making process for one specific aspect of drug discovery – the choice to move forward with the development of a new drug compound. We discussed best practices for assembling a cross functional team and developing a concise rationale for a proposed plan, and we presented a framework for future decisions that align with company goals, curating and leveraging the knowledge that is needed to maintain good decisions.

Contact us

Learn how inPhronesis can simplify your life and empower your team with expert consultants and our cloud-based system, inVision.

Chris Martin, MBA, MS


As the president of inPhronesis, Chris is focused on constantly improving inVision, the leading competitive and market intelligence platform for the biopharmaceutical industry, to better meet the changing needs of clients.


With 20 years of experience in roles being a consumer of market and competitive information, Chris understands the needs and priorities of clients. Chris was a senior principal and co-founder of inThought, a life science consulting, market research, and analytics firm. Collaborating with Ben Weintraub, Chris also co-founded BiotechTracker, an online tool for investors and precursor to inVision. Previous to inThought, he was a healthcare analyst and co-portfolio manager at two investment firms. Chris served in health care policy roles at the White House Office of Management and Budget. These roles included Medicare Desk Officer at the Office of Information and Regulatory Affairs, where he was responsible for providing recommendations to senior White House policy officials on healthcare policies and regulations.


Chris has a Master in Business Administration from Harvard Business School, a Master in Engineering from Villanova University, and a Bachelor of Science in Engineering from Cornell University. Prior to attending Harvard Business School, Chris served on two U.S. Navy nuclear submarines and at the Pentagon.